CL2020001939A1 - Administración de dosis elevadas de terapias inhaladas. - Google Patents
Administración de dosis elevadas de terapias inhaladas.Info
- Publication number
- CL2020001939A1 CL2020001939A1 CL2020001939A CL2020001939A CL2020001939A1 CL 2020001939 A1 CL2020001939 A1 CL 2020001939A1 CL 2020001939 A CL2020001939 A CL 2020001939A CL 2020001939 A CL2020001939 A CL 2020001939A CL 2020001939 A1 CL2020001939 A1 CL 2020001939A1
- Authority
- CL
- Chile
- Prior art keywords
- formulations
- administration
- high doses
- canister
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención comprende métodos y formulaciones para aumentar la carga útil de un fármaco, especialmente en terapias con polvo seco, dosificadas por inhalación, basadas en un receptáculo, donde los métodos y las formulaciones están caracterizados por una alta densidad de producto, como así también una alta TLD por receptáculo, mientras se mantiene el desempeño altamente eficiente del aerosol del dispositivo. Las realizaciones de la presente invención comprenden una composición farmacéutica en polvo secada por pulverización que comprende partículas administrables desde un inhalador de polvo seco, la composición comprende un agente activo, y un excipiente formador de recubrimiento, donde el polvo está caracterizado por una densidad de producto mayor que 50 mg/mL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862622464P | 2018-01-26 | 2018-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001939A1 true CL2020001939A1 (es) | 2021-01-04 |
Family
ID=65635769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001939A CL2020001939A1 (es) | 2018-01-26 | 2020-07-23 | Administración de dosis elevadas de terapias inhaladas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210069106A1 (es) |
EP (1) | EP3743045A1 (es) |
JP (1) | JP2021510723A (es) |
KR (1) | KR20200115560A (es) |
CN (1) | CN111526870A (es) |
AR (1) | AR114308A1 (es) |
AU (2) | AU2019212586C1 (es) |
BR (1) | BR112020014793A2 (es) |
CA (1) | CA3089439A1 (es) |
CL (1) | CL2020001939A1 (es) |
IL (1) | IL276241A (es) |
MX (1) | MX2020007745A (es) |
RU (1) | RU2020127882A (es) |
WO (1) | WO2019145897A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL292437A (en) | 2019-10-28 | 2022-06-01 | Medimmune Ltd | Dry powder formulations of antibodies that bind thymic lymphopoietin (tslp) and methods of using them |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1446104B2 (en) | 2001-11-01 | 2011-08-03 | Novartis AG | Spray drying methods |
MXPA05007154A (es) | 2002-12-30 | 2005-09-21 | Nektar Therapeutics | Atomizador prepeliculizacion. |
PL2322180T3 (pl) * | 2004-08-23 | 2015-10-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
US8900555B2 (en) * | 2006-07-27 | 2014-12-02 | Nektar Therapeutics | Insulin derivative formulations for pulmonary delivery |
TR200907236A2 (tr) * | 2009-09-23 | 2011-04-21 | Bi̇lgi̇ç Mahmut | Tiotropyum kuru toz formülasyonunun blister ambalajda taşınması. |
JOP20120023B1 (ar) * | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
WO2013130767A1 (en) * | 2012-02-29 | 2013-09-06 | Pulmatrix, Inc. | Inhalable dry powders |
US10577554B2 (en) * | 2013-03-15 | 2020-03-03 | Children's Medical Center Corporation | Gas-filled stabilized particles and methods of use |
UY36889A (es) * | 2015-09-09 | 2017-04-28 | Novartis Ag | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas |
CA2992171A1 (en) * | 2015-09-09 | 2017-03-16 | Novartis Ag | Targeted delivery of spray-dried formulations to the lungs |
EP3405241B1 (en) * | 2016-01-19 | 2020-07-08 | Novartis AG | Multidose inhaler |
CN108778249B (zh) * | 2016-01-29 | 2022-05-27 | 曼金德公司 | 干粉吸入器 |
-
2019
- 2019-01-24 AU AU2019212586A patent/AU2019212586C1/en active Active
- 2019-01-24 BR BR112020014793-1A patent/BR112020014793A2/pt not_active Application Discontinuation
- 2019-01-24 JP JP2020540345A patent/JP2021510723A/ja active Pending
- 2019-01-24 US US16/963,678 patent/US20210069106A1/en not_active Abandoned
- 2019-01-24 CA CA3089439A patent/CA3089439A1/en active Pending
- 2019-01-24 EP EP19708669.7A patent/EP3743045A1/en not_active Withdrawn
- 2019-01-24 AR ARP190100160A patent/AR114308A1/es unknown
- 2019-01-24 WO PCT/IB2019/050607 patent/WO2019145897A1/en unknown
- 2019-01-24 MX MX2020007745A patent/MX2020007745A/es unknown
- 2019-01-24 RU RU2020127882A patent/RU2020127882A/ru unknown
- 2019-01-24 KR KR1020207024324A patent/KR20200115560A/ko not_active Application Discontinuation
- 2019-01-24 CN CN201980007046.7A patent/CN111526870A/zh active Pending
-
2020
- 2020-07-23 IL IL276241A patent/IL276241A/en unknown
- 2020-07-23 CL CL2020001939A patent/CL2020001939A1/es unknown
-
2022
- 2022-04-05 AU AU2022202278A patent/AU2022202278A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020127882A (ru) | 2022-02-28 |
RU2020127882A3 (es) | 2022-02-28 |
KR20200115560A (ko) | 2020-10-07 |
AU2019212586A1 (en) | 2020-07-09 |
AU2022202278A1 (en) | 2022-04-21 |
BR112020014793A2 (pt) | 2020-12-08 |
US20210069106A1 (en) | 2021-03-11 |
MX2020007745A (es) | 2020-09-25 |
WO2019145897A1 (en) | 2019-08-01 |
AR114308A1 (es) | 2020-08-19 |
CA3089439A1 (en) | 2019-08-01 |
EP3743045A1 (en) | 2020-12-02 |
CN111526870A (zh) | 2020-08-11 |
JP2021510723A (ja) | 2021-04-30 |
IL276241A (en) | 2020-09-30 |
AU2019212586B2 (en) | 2022-01-06 |
AU2019212586C1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190738A1 (es) | Formulacion novedosa para administracion por via oral | |
BRPI0508170A (pt) | formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem | |
MX2016004316A (es) | Inhalador de polvo seco. | |
AR070834A1 (es) | Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios | |
MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
AR089805A1 (es) | FORMULACION SECA EN POLVO QUE COMPRENDE UNA CORTICOESTEROIDE Y UN b-ADRENERGICO PARA ADMINISTRAR POR INHALACION | |
BRPI0512230A (pt) | método para minimizar a retenção de pó sobre superfìcies | |
NZ708449A (en) | Devices and methods for puncturing a capsule to release a powdered medicament therefrom | |
CL2017001859A1 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol | |
AR039317A1 (es) | Proceso para la preparacion de una suspension esteril de particulas de dipropionato de beclometasona para administracion por inhalacion | |
PE20230382A1 (es) | Nueva composicion farmaceutica para administracion de farmacos | |
CL2020001939A1 (es) | Administración de dosis elevadas de terapias inhaladas. | |
AR099364A1 (es) | Inhalador de medicamentos | |
CR20140540A (es) | Nueva forma de dosificación y formulación de abediterol | |
Kaur et al. | Inhalational drug delivery in pulmonary aspergillosis | |
AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
WO2019136306A8 (en) | Intranasal delivery of levodopa powder by precision olfactory device | |
CL2018003688A1 (es) | Método y equipo de preparación de una composición de micropartículas | |
MX2015015150A (es) | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. | |
MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
MX2015012529A (es) | Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla. | |
JP2016531138A5 (es) | ||
AR107999A1 (es) | Dispositivo inhalador de aerosol | |
CO2022012207A2 (es) | Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada | |
DOP2022000004A (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad |